QIAGEN leverages QuantiFERON ®- TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased ...

QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing.On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood ...

In terms of latest development, QIAGEN’s market-leading QuantiFERON latent TB test delivered an outstanding second quarter of 2023, ...

The QuantiFERON test delivered its sixth consecutive quarter of sales above $100 million, supported by solid demand in all regions from conversion gains against the tuberculin skin test.

All ELI students from a country that has been identified as high-risk must be tested for Tuberculosis using the Quantiferon test before coming to Delaware. After taking the Quantiferon test, the ...

Qiagen sees Q1 sales up ~5% to $483M, topping prior outlook despite missing street consensus. QIAstat-Dx and QuantiFERON test drive growth; EPS raised to $2.35 amid early margin target achievement.